Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback